Skip to content
10-Q

Quarterly Report

MoonLake Immunotherapeutics MLTX

0001821586-25-000022

← back to feed
Filed
Nov 5, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q3 2025 · Sep 30, 2025 63.37M sh
Shares Diluted Q3 2025 · Sep 30, 2025 63.3M sh
Shares Diluted Q3 2025 · Sep 30, 2024 62.9M sh
Shares Diluted Q3 2025 · Sep 30, 2024 62.8M sh
Capex Q3 2025 · Sep 30, 2025 $35K
Capex restated Q3 2025 · Sep 30, 2024 $344K
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$137.21M
Operating Cash Flow restated Q3 2025 · Sep 30, 2024 −$68.11M
Long Term Debt Q3 2025 · Sep 30, 2025 $73.74M
Long Term Debt Q3 2025 · Dec 31, 2024 $0
Cash And Equivalents Q3 2025 · Sep 30, 2025 $350.74M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $180.43M
Stockholders Equity Q3 2025 · Sep 30, 2025 $288.91M
Stockholders Equity Q3 2025 · Dec 31, 2024 $446.83M
Current Liabilities Q3 2025 · Sep 30, 2025 $48.37M
Current Liabilities Q3 2025 · Dec 31, 2024 $22.46M
Total Liabilities Q3 2025 · Sep 30, 2025 $123.14M
Total Liabilities Q3 2025 · Dec 31, 2024 $24.54M
Current Assets Q3 2025 · Sep 30, 2025 $411.22M
Current Assets Q3 2025 · Dec 31, 2024 $474.29M
Total Assets Q3 2025 · Sep 30, 2025 $414.34M
Total Assets Q3 2025 · Dec 31, 2024 $477.93M
Eps Diluted Q3 2025 · Sep 30, 2025 −$1.10
Eps Diluted Q3 2025 · Sep 30, 2025 −$2.61
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.56
Eps Diluted Q3 2025 · Sep 30, 2024 −$1.17
Eps Basic Q3 2025 · Sep 30, 2025 −$1.10
Eps Basic Q3 2025 · Sep 30, 2025 −$2.61
Eps Basic Q3 2025 · Sep 30, 2024 −$0.56
Eps Basic Q3 2025 · Sep 30, 2024 −$1.17
Sga Expense Q3 2025 · Sep 30, 2025 $10.8M
Sga Expense Q3 2025 · Sep 30, 2025 $32.76M
Sga Expense restated Q3 2025 · Sep 30, 2024 $7.38M
Sga Expense restated Q3 2025 · Sep 30, 2024 $21.1M
Rd Expense Q3 2025 · Sep 30, 2025 $60.64M
Rd Expense Q3 2025 · Sep 30, 2025 $146.86M
Rd Expense restated Q3 2025 · Sep 30, 2024 $35.74M
Rd Expense restated Q3 2025 · Sep 30, 2024 $72.41M
Net Income Q3 2025 · Sep 30, 2025 −$69.73M
Net Income Q3 2025 · Sep 30, 2025 −$164.89M
Net Income restated Q3 2025 · Sep 30, 2024 −$35.39M
Net Income restated Q3 2025 · Sep 30, 2024 −$73.33M
Operating Income Q3 2025 · Sep 30, 2025 −$71.43M
Operating Income Q3 2025 · Sep 30, 2025 −$179.62M
Operating Income restated Q3 2025 · Sep 30, 2024 −$43.11M
Operating Income restated Q3 2025 · Sep 30, 2024 −$93.51M